Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications
NeurologyLive® Friday 5 — June 24, 2022
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns